The long-term safety and immunogenicity of inactivated hepatitis A was evaluated in a study involving 60 patients with chronic liver disease (CLD) (56 patients with chronic hepatitis B, and 4 patients with chronic hepatitis C).A two-dose schedule, 1440 ELISA units of the inactivated hepatitis A vaccine was given at 0 and 6 months, which produced 100% antibodies to hepatitis A virus (anti-HAV) seroconversion (Lee et aI., J Med Virol 1997;52:215-8).Patients in the study were followed up annually for 5 years.and in that time, 2 fatalities were reported.One 21-year-old male chronic hepatitis B patient died following liver transplantation at 3 years 6626